Incyte unveils positive results from Phase 2 ruxolitinib cream study
Category: #health  By Pankaj Singh  Date: 2019-10-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Incyte unveils positive results from Phase 2 ruxolitinib cream study

Vitiligo is a prominent skin diseases prevalent across the world that causes skin color loss. The disease is increasingly being taken as a serious issue by various pharmaceutical firms across the globe, who are continuously working towards finding a better treatment to cure this skin disease.

Incyte Corporation, a US based pharmaceutical firm headquartered in Delaware, reportedly announced the positive 52-week results from the company’s dose-ranging, double-blind and randomized, Phase 2 clinical trial evaluating ruxolitinib cream, an anti-inflammatory, nonsteroidal, JAK inhibitor treatment, in adults with vitiligo.

As announced by the firm earlier, the trial met its primary endpoint, showcasing that significantly more patients who were treated with ruxolitinib over a span of 24 weeks attained an improvement of ≥50% from baseline results in the F-VASI50 (facial vitiligo area severity index) score in comparison with the patients who were treated with a non-medicated cream. 

New results seen at week 52 demonstrate significant improvements in full body repigmentation when treated with ruxolitinib cream, calculated by the patient proportion achieving more than or equal to 50% improvement from the baseline in the total T-VASI50 (vitiligo area severity index), a vital secondary endpoint.     

Additionally, after the 52 week-long therapy with 1.5% ruxolitinib cream administered twice daily, 51% patients obtained a greater than or equal to 75% improvement (F-VASI75) and 58% patients achieved F-VASI50. After approximately 24 weeks, F-VASI75 is the primary measure of outcome of both TRuE-V2 and TRuE-V1 randomized Phase 3 clinical trials that are already under progress.

Group Vice President, Inflammation & Autoimmunity at Incyte, Jim Lee, M.D. stated that the company is very encouraged seeing the new positive data showcased at EADV, which demonstrates significant facial as well as total body repigmentation of the vitiligo lesions in patients who were treated by ruxolitinib cream, and continued enhancements with a treatment of longer duration.

Lee added that as the company seeks to provide a highly-needed option for the patients affected by this life changing disease, it is thrilled that pivotal Phase 3 trials which are evaluating ruxolitinib cream in patients with vitiligo are under progress, with their results predicted to be released in 2021.    

 

 

 

 

 

 

 

 

Source credit : https://investor.incyte.com/news-releases/news-release-details/incyte-announces-positive-52-week-results-randomized-phase-2



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Yahoo Japan explores plans for a merger with Navers Line app
Yahoo Japan explores plans for a merger with Navers Line app
By Pankaj Singh

Yahoo! Japan Corp., a Japanese internet firm, has recently cleared the fog on its merger with trending messaging app Line. According to reports, the merger would see the formation of a new internet group that would cov...

Skyroam Solis X launched online for purchase or rental options
Skyroam Solis X launched online for purchase or rental options
By Pankaj Singh

In this era of smart technologies and digitalization, the need for high speed internet connectivity have been doing rounds globally. To suffice these requirements, Skyroam Hotspot has taken a step forward to equip its ...

Spell & The Gypsy Collective rolled out on Workarea Commerce Cloud
Spell & The Gypsy Collective rolled out on Workarea Commerce Cloud
By Pankaj Singh

Workarea Commerce, a renowned commerce platform for new merchants across various sectors, and Syatt Media, a Canada based e-commerce agency with deep platform and industry expertise, announced that Spell & The Gyps...